Hadrien Bouchez

Hadrien Bouchez is a Partner at Kurma Partners, a prominent European venture capital firm specializing in healthcare and biotechnology, where involvement spans from company creation to growth capital investment since September 2014. With extensive experience in the biotechnology sector, Hadrien serves as a Board Director for Memo Therapeutics AG and Ermium Therapeutics, as well as a Board Observer for Xeltis and Flamingo Therapeutics. Previously, Hadrien held an Analyst position at Servier focused on drug acquisition and in-licensing. Hadrien's academic background includes a Pharm.D. from the University of Lille 1 Sciences and Technology, a Master's degree in Pharmacy from the University of Geneva, and advanced qualifications in Corporate Finance and Entrepreneurship from HEC Paris and ESSEC Business School, respectively.